Scientists have identified four biomarkers that may help resolve the difficult differential diagnosis between malignant pleural mesothelioma (MPM) and non-cancerous pleural tissue with reactive…
Researchers at the University of Illinois at Chicago College of Medicine have discovered a protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that…
Meaningful long-term survival is possible for selected patients suffering from advanced cancer of the abdomen when treated with cytoreductive surgery with Hyperthermic IntraPeritoneal Chemotherapy…
A novel approach to cancer immunotherapy – strategies designed to induce the immune system to attack cancer cells – may provide a new and cost-effective weapon against some of the most deadly…
Pleural mesothelioma, is an aggressive form of lung cancer strongly linked to asbestos exposure, which has very limited treatment options and is associated with poor patient survival, with most…
An important survey has launched that will help to inform future research into mesothelioma diagnosis, treatments and care. The survey is now available at www.psp.nihr.ac.
The investigational monoclonal antibody amatuximab (development code: MORAb-009), has been granted orphan drug designation (ODD) for the treatment of malignant mesothelioma by the European Commission.
Results of clinical research that treated mesothelioma with radiation before surgery show the three-year survival rate more than doubled for study participants afflicted with this deadly disease…
Engineered immune cells, called CARTmeso cells, designed to direct antitumor immune responses toward tumors that carry a protein called mesothelin, showed antitumor activity in two patients with…
Home renovators are being encouraged to extend their ‘DIY’ skills and take a free online course to help them identify and safely handle asbestos.
Scientists researching one of Britain’s deadliest rare cancers, mesothelioma, at Queen Mary’s Barts Cancer Institute studied how cancer cells are not able to survive and continue growing when starved…
For the first time, researchers from the Perelman School of Medicine at the University of Pennsylvania have shown the predictive power of a group of overlooked lymph nodes–known as the posterior…
University of Leicester researchers are leading two major trials into treatments for a type of cancer which affects those exposed to asbestos.
A new targeted therapy for asbestos-related tumours has shown promise in an animal model.
Malignant mesothelioma is a rare asbestos-associated malignancy with limited therapeutic options. Despite advances in the treatment, the median survival remains 12 months from the time of diagnosis.